Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amarin Corp ADR (AMRN)

Amarin Corp ADR (AMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 309,816
  • Shares Outstanding, K 20,793
  • Annual Sales, $ 228,610 K
  • Annual Income, $ -82,180 K
  • EBIT $ -96 M
  • EBITDA $ -93 M
  • 60-Month Beta 0.72
  • Price/Sales 1.36
  • Price/Cash Flow N/A
  • Price/Book 0.68

Options Overview Details

View History
  • Implied Volatility 62.75% (-0.08%)
  • Historical Volatility 62.63%
  • IV Percentile 1%
  • IV Rank 0.78%
  • IV High 1,253.62% on 04/24/25
  • IV Low 53.42% on 08/29/25
  • Expected Move (DTE 35) 3.12 (20.94%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 229
  • Volume Avg (30-Day) 186
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 6,749
  • Open Int (30-Day) 6,089
  • Expected Range 11.78 to 18.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.06
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -2.04
  • Prior Year -2.40
  • Growth Rate Est. (year over year) +55.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.12 +14.40%
on 01/05/26
16.80 -10.65%
on 01/09/26
+1.04 (+7.44%)
since 12/16/25
3-Month
13.12 +14.40%
on 01/05/26
20.90 -28.18%
on 10/24/25
-5.06 (-25.21%)
since 10/16/25
52-Week
7.08 +112.01%
on 03/12/25
20.90 -28.18%
on 10/24/25
+3.93 (+35.47%)
since 01/16/25

Most Recent Stories

More News
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on recent...

AMRN : 15.01 (+0.74%)
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities

DUBLIN and BRIDGEWATER, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced select...

AMRN : 15.01 (+0.74%)
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new  post...

AMRN : 15.01 (+0.74%)
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

DUBLIN and BRIDGEWATER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be...

AMRN : 15.01 (+0.74%)
Amarin Reports Third Quarter 2025 Financial Results

Company completes transition to fully partnered commercialization model across all international markets Q3 2025 performance reflects initial impact of new approach to Europe, ongoing expansion of...

AMRN : 15.01 (+0.74%)
Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit

DUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today issued the following...

AMRN : 15.01 (+0.74%)
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced that...

AMRN : 15.01 (+0.74%)
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, in collaboration with...

AMRN : 15.01 (+0.74%)
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted in vitro data assessing the effects of EPA on lipoprotein(a) [Lp(a)]...

AMRN : 15.01 (+0.74%)
New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or Very High-Risk Patients Based on REDUCE-IT -- DUBLIN and BRIDGEWATER,...

AMRN : 15.01 (+0.74%)

Business Summary

Amarin Corporation plc is a commercial-stage pharmaceutical company focused on developing therapies, especially based on omega-3 fatty acid for treating cardiovascular diseases. The company's sole marketed drug, Vascepa (icosapent ethyl) is approved in the United States as an adjunct to diet for treating...

See More

Key Turning Points

3rd Resistance Point 15.60
2nd Resistance Point 15.41
1st Resistance Point 15.16
Last Price 15.01
1st Support Level 14.72
2nd Support Level 14.53
3rd Support Level 14.28

See More

52-Week High 20.90
Fibonacci 61.8% 15.62
Last Price 15.01
Fibonacci 50% 13.99
Fibonacci 38.2% 12.36
52-Week Low 7.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar